RESUMO
The outcome of 110 patients with paediatric onset mucopolysaccharidosis II (MPS II) since the commercial introduction of enzyme replacement therapy (ERT) in England in 2007 is reported. Median length of follow up was 10â¯years 3â¯months (rangeâ¯=â¯1â¯y 2â¯m to 18â¯years 6â¯month). 78 patients were treated with ERT, 18 had no ERT or disease modifying treatment 7 had haematopoietic stem cell transplant, 4 experimental intrathecal therapy and 3 were lost to follow up. There is clear evidence of improved survival (median age of death of ERT treated (nâ¯=â¯16)â¯=â¯15.13â¯years (rangeâ¯=â¯9.53 to 20.58â¯y), and untreated (nâ¯=â¯17)â¯=â¯11.43â¯y (0.5 to 19.13â¯y) pâ¯=â¯.0005). Early introduction of ERT improved respiratory outcome at 16â¯years, the median FVC (% predicted) of those in whom ERT initiated <8â¯yearsâ¯=â¯69% (rangeâ¯=â¯34-86%) and 48% (25-108) (pâ¯=â¯.045) in those started >8â¯years. However, ERT appears to have minimal impact on hearing, carpal tunnel syndrome or progression of cardiac valvular disease. Cardiac valvular disease occurred in 18/46 (40%), with progression occurring most frequently in the aortic valve 13/46 (28%). The lack of requirement for neurosurgical intervention in the first 8â¯years of life suggests that targeted imaging based on clinical symptomology would be safe in this age group after baseline assessments. There is also emerging evidence that the neurological phenotype is more nuanced than the previously recognized dichotomy of severe and attenuated phenotypes in patients presenting in early childhood.
Assuntos
Terapia de Reposição de Enzimas , Mucopolissacaridose II/tratamento farmacológico , Adolescente , Criança , Pré-Escolar , Coleta de Dados , Progressão da Doença , Inglaterra , Seguimentos , Humanos , Lactente , Mucopolissacaridose II/mortalidade , Fenótipo , Estudos Retrospectivos , Fatores de Tempo , Resultado do TratamentoRESUMO
Controlled fasts can play a valuable role in the diagnosis and management of hypoglycaemia in paediatric clinical practice, but are no substitute for the collecting of appropriate critical samples at the time of hypoglycaemia for metabolic and endocrine studies. Fatty acid oxidation defects, hyperinsulinism and adrenal insufficiency should always be excluded prior to organising controlled fasts. Controlled fasts are safe if conducted in an experienced setting with strict protocols in place. Failure to adhere to protocol can defeat the purpose of the study and can potentially be dangerous. Proper planning in conjunction with the laboratory and close supervision by staff experienced in controlled fasts is crucial to ensure the best quality information is yielded from these procedures.
Assuntos
Jejum , Hipoglicemia/diagnóstico , Hipoglicemia/etiologia , Hipoglicemia/terapia , Glicemia/metabolismo , Criança , Técnicas de Laboratório Clínico , Diagnóstico Diferencial , Diagnóstico Precoce , HumanosRESUMO
Late-onset LAL deficiency, previously referred to as cholesteryl ester storage disorder, is a rare lysosomal storage disorder characterized by accumulation of cholesteryl esters. It has a heterogeneous clinical phenotype including abdominal pain, poor growth, hyperlipidemia with vascular complications and hepatosplenomegaly. End-stage liver disease may occur, but there are few reports of successful LT. There are also concerns that systemic manifestations of the disease might persist post-LT. We report a case with excellent outcome eight yr following LT. The subject was noted to have asymptomatic hepatosplenomegaly during an intercurrent illness, and LAL deficiency was confirmed with compound heterozygosity in the LIPA. Despite dietary fat restriction, he developed signs of progressive liver disease and subsequently developed hepatopulmonary syndrome. He underwent cadaveric LT at the age of nine and a half yr and recovered with prompt resolution of hepatopulmonary syndrome. Eight yr post-transplant he has normal growth, normal lipid profile, and liver and renal function tests. Liver histology showed no evidence of disease recurrence at this stage. LT in this subject resulted in an excellent functional correction of late-onset LAL deficiency.